INS and COVID-19: Regarding the need for hospitalization (Figure 1A), the breakdown is as follows: among subjects treated with metformin, 1.8% required hospitalization due to COVID-19, and 0.8% for other reasons; within the group receiving insulin/insulin secretagogues, 3.2% were hospitalized for COVID-19, and 1.9% for other reasons.